The PCSK9-REACT study found that, in patients with a recent acute coronary syndrome (ACS) undergoing percutaneous coronary intervention and receiving P2Y12 inhibitor, there was a direct association between PCSK9 plasma level and high-on-treatment platelet reactivity (14). This evidence concerns the gene PCSK9 and acute coronary syndrome.